Affordable Access

Access to the full text

Effect of first-line biologic initiation on glucocorticoid exposure in children hospitalized with new-onset systemic juvenile idiopathic arthritis: emulation of a pragmatic trial using observational data

Authors
  • Peterson, Rosemary G.1, 2, 3
  • Xiao, Rui4
  • Katcoff, Hannah2
  • Fisher, Brian T.2, 5, 4
  • Weiss, Pamela F.1, 2, 4
  • 1 Children’s Hospital of Philadelphia, Division of Rheumatology, Philadelphia, PA, USA , Philadelphia (United States)
  • 2 Children’s Hospital of Philadelphia Research Institute, Philadelphia, PA, USA , Philadelphia (United States)
  • 3 Dell Children’s Medical Center, Strictly Pediatrics Building, 1301 Barbara Jordan Blvd, Suite 400, Austin, TX, 78723, USA , Austin (United States)
  • 4 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA , Philadelphia (United States)
  • 5 Children’s Hospital of Philadelphia, Division of Infectious Diseases, Philadelphia, PA, USA , Philadelphia (United States)
Type
Published Article
Journal
Pediatric Rheumatology
Publisher
Springer Science and Business Media LLC
Publication Date
Jul 05, 2021
Volume
19
Issue
1
Identifiers
DOI: 10.1186/s12969-021-00597-z
Source
Springer Nature
Keywords
Disciplines
  • Research Article
License
Green

Abstract

BackgroundGlucocorticoid exposure is a significant driver of morbidity in children with systemic juvenile idiopathic arthritis (sJIA). We determined the effect of early initiation of biologic therapy (IL-1 or IL-6 inhibition) on glucocorticoid exposure in hospitalized patients with new-onset sJIA.MethodsWe emulated a pragmatic sequence of trials (“pseudo-trials”) of biologic initiation in children (≤ 18 years) hospitalized with new-onset sJIA utilizing retrospective data from an administrative database from 52 tertiary care children’s hospitals from 2008 to 2019. Eligibility window, treatment assignment and start of follow-up between biologic and non-biologic study arms were aligned for each pseudo-trial. Patients in the source population could meet eligibility criteria at several timepoints. Mixed-effects logistic regression was used to determine the effect of biologic initiation on in-hospital glucocorticoid exposure.ResultsFour hundred sixty-eight children met eligibility criteria, of which 19% received biologic therapy without preceding or concomitant initiation of immunomodulatory medications. This proportion significantly increased over time during the study period (p < 0.01). 1451 trial subjects were included across 4 pseudo-trials with 71 assigned to the biologic arm and 1380 assigned to the non-biologic arm. After adjustment, there was a trend toward decreased odds of glucocorticoid initiation in the biologic arm compared to the non-biologic arm (OR 0.39, 95% CI [0.13, 1.15]).ConclusionBiologic initiation in children hospitalized with new-onset sJIA significantly increased over time and may be associated with reduced glucocorticoid exposure. The increasing use of first-line biologic therapy may lead to clinically relevant reductions in treatment-related adverse effects of glucocorticoid-reliant therapeutic approaches.

Report this publication

Statistics

Seen <100 times